{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:34:00Z","timestamp":1779878040474,"version":"3.53.1"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,3,13]]},"abstract":"<jats:p> PURPOSE: To report our experience with both <jats:sup>123<\/jats:sup>I-vasoactive intestinal peptide (VIP) and <jats:sup>111<\/jats:sup>In-DTPA-D-Phe<jats:sup>1<\/jats:sup>-octreotide for imaging to identify primary and metastatic tumor sites in carcinoid patients. <\/jats:p><jats:p> PATIENTS AND METHODS: One hundred ninety-four patients with a verified or clinically suspected diagnosis of a carcinoid tumor were injected with <jats:sup>111<\/jats:sup>In-DTPA-D-Phe<jats:sup>1<\/jats:sup>-OCT for imaging purposes, while 133 patients underwent scanning with both <jats:sup>123<\/jats:sup>I-VIP and <jats:sup>111<\/jats:sup>In-DTPA-D-Phe<jats:sup>1<\/jats:sup>-OCT in random order. Imaging results were compared with computed tomography scans, results of conventional ultrasound, endosonography, and endoscopy, and results of surgical exploration in case of inconclusive conventional imaging. <\/jats:p><jats:p> RESULTS: Primary or recurrent carcinoid tumors could be visualized with <jats:sup>111<\/jats:sup>In-DTPA-D-Phe<jats:sup>1<\/jats:sup>-OCT in 95 (91%) of 104 patients; metastatic sites were identified in 110 (95%) of 116 patients. In 11 (51%) of 21 patients with suggestive symptoms but without identified lesions by conventional imaging, focal tracer uptake located the carcinoid tumor. In addition, metastatic disease was demonstrated in three patients after resection. In a direct comparison in the 133 patients who underwent both imaging modalities, <jats:sup>111<\/jats:sup>In-DTPA-D-Phe<jats:sup>1<\/jats:sup>-OCT was found to be superior to <jats:sup>123<\/jats:sup>I-VIP, with 35 (93%) of 38 versus 32 (82%) of 38 scans being positive in primary or recurrent tumors, 58 (90%) of 65 versus 53 (82%) of 65 being positive in patients with metastatic sites, and seven (44%) of 16 versus four (25%) of 16 being positive in patients with symptoms but otherwise negative work-ups. Overall, additional lesions not seen on conventional imaging were imaged in 43 (41%) of 158 versus 25 (25%) of 103 scans with <jats:sup>111<\/jats:sup>In-DTPA-D-Phe<jats:sup>1<\/jats:sup>-OCT and <jats:sup>123<\/jats:sup>I-VIP, respectively. <\/jats:p><jats:p> CONCLUSION: Both peptide tracers have a high sensitivity for localizing tumor sites in patients with ascertained or suspected carcinoid tumors, with <jats:sup>111<\/jats:sup>In-DTPA-D-Phe<jats:sup>1<\/jats:sup>-OCT scintigraphy being more sensitive than <jats:sup>123<\/jats:sup>I-VIP receptor scanning. Both, however, had a higher diagnostic yield than conventional imaging, as verified by surgical intervention or long-term follow-up. The combination of both peptide receptor scans does not seem to further enhance diagnostic information. <\/jats:p>","DOI":"10.1200\/jco.2000.18.6.1331","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:16:39Z","timestamp":1487920599000},"page":"1331-1336","source":"Crossref","is-referenced-by-count":53,"title":["Value of Peptide Receptor Scintigraphy Using <sup>123<\/sup>I-Vasoactive Intestinal Peptide and <sup>111<\/sup>In-DTPA-D-Phe1-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998"],"prefix":"10.1200","volume":"18","author":[{"given":"Markus","family":"Raderer","sequence":"first","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Kurtaran","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Leimer","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Angelberger","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Niederle","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Vierhapper","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Vorbeck","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H. L.","family":"Hejna","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Scheithauer","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Pidlich","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Virgolini","sequence":"additional","affiliation":[{"name":"From the Departments of Internal Medicine INuclear Medicine, Internal Medicine III, Internal Medicine IV, Surgery, and Radiology, University of Vienna, and Research Center Seibersdorf, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0179","doi-asserted-by":"crossref","unstructured":"Moertel  CG:  Karnovsky Memorial Lecture:  An odyssey in the land of small tumors. J Clin Oncol 5:1503,1987-1522,","DOI":"10.1200\/JCO.1987.5.10.1502"},{"key":"R2-0179","unstructured":"Kvols  L:  Medical oncology considerations in patients with metastastic neuroendocrine tumors.  Semin Oncol 21:56,1994-60,   (suppl 13)"},{"key":"R3-0179","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800770102"},{"key":"R6-0179","doi-asserted-by":"publisher","DOI":"10.3109\/00365529209000106"},{"key":"R7-0179","unstructured":"Macgillivray  DC,  Snyder  DA,  Drucker  W, et al:  Carcinoid tumors:  The relationship between clinical presentation and the extent of disease. Surgery 110:68,1991-72,"},{"key":"R8-0179","doi-asserted-by":"crossref","unstructured":"Vinik  AI,  McLeod  MK,  Fig  LM, et al:  Clinical features, diagnosis, and localization of carcinoid tumors and their management.  Gastroenterol Clin North Am 18:865,1989-896,","DOI":"10.1016\/S0889-8553(21)00446-5"},{"key":"R9-0179","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4"},{"key":"R10-0179","doi-asserted-by":"crossref","unstructured":"Jonas  S,  John  M,  Boese-Landgraf  J, et al:  Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.  Langenbecks Arch Chir 380:90,1995-95,","DOI":"10.1007\/BF00186414"},{"key":"R11-0179","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91258-0"},{"key":"R12-0179","doi-asserted-by":"crossref","unstructured":"Krenning  EP,  Kwekkeboom  DJ,  Bakker  WH, et al:  Somatostatin receptor scintigraphy with (In-DTPA-D-Phe)- and (I-Thyr)-octreotide:  The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 18:1,1993-16,  111 1 123 3","DOI":"10.1007\/BF00181765"},{"key":"R13-0179","unstructured":"Krenning  EP,  Bakker  WH,  Kooij  PP, et al:  Somatostatin receptor scintigraphy with indium -DTPA-D-Phe-octreotide in man:  Metabolism, dosimetry and comparison with iodine Tyr-octreotide. J Nucl Med 33:652,1992-658,  111 1 123 3"},{"key":"R14-0179","doi-asserted-by":"publisher","DOI":"10.1007\/BF01367597"},{"key":"R15-0179","doi-asserted-by":"publisher","DOI":"10.1126\/science.169.3951.1217"},{"key":"R16-0179","doi-asserted-by":"publisher","DOI":"10.1038\/343564a0"},{"key":"R17-0179","doi-asserted-by":"crossref","unstructured":"Cohn  J:  Vasoactive intestinal peptide stimulates protein phosphorylation in a colonic epithelial cell line.  Am J Physiol 16:420,1987-424,","DOI":"10.1152\/ajpgi.1987.253.3.G420"},{"key":"R18-0179","doi-asserted-by":"crossref","unstructured":"Battari  A,  Martin  JM,  Luis  J, et al:  Solubilization of the vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells.  J Biol Chem 263:17685,1988-17689,","DOI":"10.1016\/S0021-9258(19)77891-0"},{"key":"R19-0179","unstructured":"Gespach  C,  Bawab  W,  de Cremoux  P, et al:  Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancers.  Cancer Res 48:5079,1988-5083,"},{"key":"R20-0179","unstructured":"Virgolini  I,  Yang  Q,  Li  SR, et al:  Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor membrane receptors.  Cancer Res 54:690,1994-700,"},{"key":"R21-0179","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410273311703"},{"key":"R22-0179","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.21.1666"},{"key":"R23-0179","unstructured":"Virgolini  I,  Kurtaran  A,  Raderer  M, et al:  Vasoactive intestinal peptide receptor scintigraphy.  J Nucl Med 36:1732,1995-1739,"},{"key":"R24-0179","unstructured":"Raderer  M,  Becherer  A,  Kurtaran  A, et al:  Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.  J Nucl Med 37:1480,1996-1487,"},{"key":"R25-0179","unstructured":"Kurtaran  A,  Raderer  M,  M\u00fcller  C, et al:  Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastases.  J Nucl Med 38:880,1997-881,"},{"key":"R26-0179","doi-asserted-by":"crossref","unstructured":"Raderer  M,  Kurtaran  A,  Hejna  M, et al:  I-Vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.  Br J Cancer 78:1,1998-5,  123","DOI":"10.1038\/bjc.1998.433"},{"key":"R27-0179","unstructured":"Raderer  M,  Kurtaran  A,  Yang  Q, et al:  I-Vasoactive intestinal peptide (VIP)-receptor scanning in patients with pancreatic cancer:  A novel tool in the diagnostic armamentarium. J Nucl Med 39:1570,1998-1575,  123"},{"key":"R28-0179","unstructured":"Krenning  EP,  Kwekkeboom  D,  de Jong  M, et al:  Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.  Semin Oncol 5:6,1994-14,   (suppl 13)"},{"key":"R29-0179","doi-asserted-by":"crossref","unstructured":"Van Eijck  C,  de Jong  M,  Breeman  W, et al:  Somatostatin receptor imaging and therapy of pancreatic tumors.  Ann Oncol 10:S177,1999\u2013S181,   (suppl 4)","DOI":"10.1093\/annonc\/10.suppl_4.S177"},{"key":"R30-0179","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.066_c.x"},{"key":"R31-0179","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.73.861.399"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.6.1331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:43:07Z","timestamp":1653514987000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.6.1331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,13]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,3,13]]}},"alternative-id":["10.1200\/JCO.2000.18.6.1331"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.6.1331","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3,13]]}}}